--- title: 'Director, CMC Management at Attovia Therapeutics' canonical: 'https://feeny.ai/job/director-cmc-management-attovia-therapeutics-san-carlos-7k9mpk16fpbm' type: 'job' last_seen: '2026-11-06' --- # Director, CMC Management at Attovia Therapeutics - **Company:** Attovia Therapeutics - **Location:** San Carlos, CA - **Compensation:** $200k–$250k - **Employment:** full-time - **Work type:** onsite - **Posted:** 2026-09-03 - **Last confirmed live:** 2026-11-06 - **Apply:** https://jobs.lever.co/attovia-therapeutics/a2315c50-db73-44a4-95c9-302ff22093c9 ## Job description Attovia Therapeutics, Inc., is seeking a Director of CMC management to lead CMC regulatory strategy, submissions, and support the activities of our external CDMO for our biologics pipeline.  Reporting to the Head of CMC, this role is responsible for preparation of CMC regulatory filings, providing technical guidance to CDMO on drug substance and drug product development and manufacturing, and ensuring CMC compliance with all applicable regulations. This role partners closely with Quality, Portfolio management, and Regulatory Affairs teams to ensure timely delivery of CMC regulatory sections and timely supply of clinical products. ## Key Responsibilities CMC Regulatory - Develop CMC regulatory strategy aligned with product development pipeline and clinical pathways - Identify and interpret applicable regulations, ICH guidelines, and agency expectations for CMC compliance - Author the CMC sections of regulatory filing and partner with Regulatory Affairs to ensure they are complete on time - Manage manufacturing-related responses and regulatory correspondence - Ensure CDMO manufacturing data, site information, and quality documentation are organized for regulatory submissions CDMO Management - Provide technical guidance to CDMO on process development, analytical method development, formulation optimization, manufacturing, etc. to ensure CMC compliance with all regulatory requirements - Coordinate with Quality team on batch testing, release criteria, and manufacturing data review - Support supply chain management including shipment of non-clinical and clinical materials from CDMO Strategic Collaborations - Collaborate with internal functions on regulatory strategy, program timelines, manufacturing milestones, and CMC deliverables. - Ensure CMC activities align with clinical development, regulatory submissions, and commercial launch timelines - Work with external CMC consultants and support the development of commercial CMC strategy aligned with regulatory pathway ## Basic Qualifications - Ph.D. in Chemistry, Biochemistry, Chemical Engineering, Pharmaceutical Sciences, or related field - 10+ years of biopharmaceutical CMC development or regulatory affair experience - Experience in process development, analytical methods, or formulation of protein therapeutics - Deep regulatory knowledge and experience with FDA/EMA submissions ## Preferred Qualifications - Cross functional experience leading or coordinating CMC development in a biotech or pharmaceutical company - Experience in managing CMC transitions from development to commercial manufacturing and supporting BLA filing - Strong technical writing, investigative, and risk assessment skills. - Ability to work independently and manage multiple vendor relationships with minimal direct supervision ## About Attovia Attovia™ is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need.  Our product candidates are internally discovered using our proprietary ATTOBODY™ platform, an evolution-driven, high-throughput biologics platform that enables the rapid discovery and creation of diverse biparatopic complex biologics.  Our pipeline spans chronic pruritic diseases, inflammatory skin diseases, inflammatory bowel disease, and other immune-mediated conditions. Our culture is centered around five core pillars: - Integrity - Learning & Growth - Drive for Excellence - Innovation - Teamwork & Collaboration We take pride in fostering a strong team and dynamic work environment, and we are seeking individuals who align with our values and contribute to a positive and impactful workplace. Attovia is located in San Carlos, CA. Attovia is an equal opportunity employer. All applicants will be considered for employment without attention to race, color, religion, sex, sexual orientation, gender identity, national origin, veteran or disability status. Learn more about Attovia: [www.attovia.com](https://www.attovia.com) Notice to Employment Agencies The Attovia talent acquisition program is managed through internal resources, and unsolicited referrals and resumes are not accepted from employment agencies, unless advance written authorization is granted from the Human Resources department. Attovia shall not be liable for any fees arising from any unsolicited or unauthorized candidate information received relative to position vacancies. ## About Attovia Therapeutics ## Company Overview - **One-liner**: Clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases using its proprietary ATTOBODY biparatopic biologics platform. - **Entity Type**: Private (S-1 filed for IPO) - **Headquarters**: San Carlos, California, USA - **Founded**: 2023 - **Founders**: Founded by a group of investors including Alamar Biosciences, Inc. (individual founders not publicly named) ## Core Business - **Primary industry/industries**: Biopharmaceuticals, immune-mediated diseases (dermatology, gastroenterology/IBD, respiratory) - **Target customers**: B2B (potential partnerships with larger pharma); ultimately patients with high unmet medical need - **Mission or purpose statement**: To develop new and improved treatments for patients in need by combining scientific curiosity with impactful change, leveraging the ATTOBODY platform to design novel complex biologics. ## Products & Services - **ATTOBODY Platform**: Proprietary evolution-driven, high-throughput discovery platform that creates biparatopic (two VHH domains) biologics with ultra-high affinity, modularity, and the ability to target two, three, or four disease-driving pathways in a single molecule. Designed for rapid candidate generation and de-risked development. - **ATTO-1310**: Monospecific ATTOBODY targeting IL-31. Completed Phase 1 clinical trial dosing in healthy volunteers and patients (Q1 2026). Indications: chronic pruritus, atopic dermatitis, chronic pruritus of unknown origin, cholestatic pruritus, CKD-associated pruritus. - **ATTO-2306**: Bispecific ATTOBODY targeting IL-13 and IL-31. In IND-enabling studies; Phase 1 expected first half of 2027. Indications: inflammatory skin diseases (atopic dermatitis, chronic spontaneous urticaria, prurigo nodularis). - **ATTO-1091**: Trispecific ATTOBODY-based Fc-fusion protein targeting TL1A, IL-23p19, and integrin α4β7. In IND-enabling studies; Phase 1 expected first half of 2027. Indications: inflammatory bowel disease (ulcerative colitis, Crohn’s disease). - **Early-stage pipeline (ATTO-006, ATTO-007, ATTO-008)**: Pre-discovery programs targeting TRM survival, immune cell survival, and multi-alarmin blockade for rheumatology, IBD, respiratory (asthma, COPD). ## Market Standing - **Valuation/Market Cap**: Not disclosed (private; S-1 filed indicates intent to raise capital via IPO) - **Key Metric**: Total funding not publicly disclosed; S-1 filing represents first public financial disclosure. The company is pre-revenue (clinical-stage). - **Notable Investors/Partners**: Alamar Biosciences (in-licensor of ATTOBODY platform). Additional founding investors not named in public filings. - **Growth Signals**: Completed Phase 1 for lead candidate ATTO-1310 within ~2 years of founding; headcount grew 35.9% year-over-year to ~40 employees; pipeline expanding into three therapeutic areas with three candidates in IND-enabling studies. ## Competitive Advantages - **ATTOBODY platform differentiator**: Biparatopic binding enables ultra-high affinity and potency, tunable pharmacokinetics, and modular design for multispecifics (bispecifics, trispecifics, conditional “AND” gate biologics). - **Speed of discovery**: Evolution-based high-throughput screening allows rapid nomination of multiple candidates (three within first two years). - **Targeting clinically validated pathways**: Focus on pathways with proven commercial and clinical precedent (IL-31, IL-13, TL1A, IL-23, integrin α4β7), reducing biological risk. - **Robust drug-like properties**: ATTOBODIES exhibit IgG-like stability and developability, potentially enabling infrequent dosing. ## Strategic Focus - Advance ATTO-1310 through clinical development for pruritus and atopic dermatitis. - Progress ATTO-2306 and ATTO-1091 into Phase 1 trials in 2027. - Expand early-stage pipeline into respiratory and additional inflammatory indications. - Leverage platform to create next-generation complex biologics that improve upon current standards of care. - Execute IPO to fund pipeline advancement and platform expansion. ## Why Work Here - **Culture**: Values-driven environment emphasizing integrity, continuous learning, drive for excellence, innovation, and teamwork. Described as a community of passionate scientists, inspiring leaders, and visionary executives. - **Benefits**: Comprehensive medical/dental/vision with company premium contributions, FSA/HSA, competitive PTO and sick leave, supplemental parental leave, commute assistance, 401(k) with employer match (immediate vesting), equity grants, educational assistance, and mentorship program. - **Work environment**: Likely on-site in San Carlos, CA (no explicit remote/hybrid policy stated). Small but rapidly growing team (~40 employees) with a flat, collaborative structure. - **Engineering/Research culture**: High autonomy, data-driven decision-making, and focus on transformative science. Employees are encouraged to push boundaries and drive progress. ## Sources 1. [linkedin.com](https://linkedin.com/company/attovia-therapeutics) – Employee data, executives, growth 2. [attovia.com](https://www.attovia.com/careers/) – Careers page, culture, benefits 3. [attovia.com](https://www.attovia.com/pipeline/) – Pipeline overview, platform description 4. [sec.gov](https://www.sec.gov/Archives/edgar/data/2058707/000119312526303256/d40469ds1.htm) – S-1 filing, business description, financials 5. [cbinsights.com](https://www.cbinsights.com/company/attovia-therapeutics) – Profile summary, founding year, headquarters ## Other roles at Attovia Therapeutics - [Associate Director, Strategic Insights](https://feeny.ai/job/associate-director-strategic-insights-attovia-therapeutics-san-carlos-668dcheeceaw) — San Carlos, CA